Roche looks to pipeline as Q3 sales-growth stalls
This article was originally published in Scrip
Executive Summary
After largely disappointing year-to-date sales, Roche's CEO Severin Schwan has highlighted the investigational products MetMAb and T-DM1 as possible long-term growth drivers.